Drug intelligence / Profile preview

SoftOx Biofilm Eradicator

Development stage: Phase 1
Lead developer: SoftOx Solutions
Modality: Small Molecules
Administration: Topical

Overview

**SoftOx Biofilm Eradicator** is an investigational topical anti-infective wound-care drug developed for chronic leg wounds, including venous leg ulcers. It is a fixed antimicrobial solution composed of hypochlorous acid and acetic acid. The formulation is designed to penetrate wound biofilms and exert broad-spectrum, non-target-specific microbicidal activity against biofilm-embedded microbes, including antibiotic-resistant bacteria. In the completed first-in-human Phase 1 SBE-01 study, the product was reported to be safe and well tolerated, with reductions in wound bioburden and exploratory signals of wound-size reduction. ([soft-ox.com](https://soft-ox.com/scientific-publications/))

Other names: SBE

Targets

Lipid A

Beyond the preview

Go deeper on SoftOx Biofilm Eradicator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SoftOx Biofilm Eradicator.

Explore the full profile